Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma
Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.
EP: 1.Intrahepatic Cholangiocarcinoma Overview
EP: 2.Risk Factors Leading to Various Liver Cancers
EP: 3.Clinical Presentations of Patients With Cholangiocarcinoma
EP: 4.The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma
EP: 5.First- and Second-Line Treatment Options for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions or Alterations
EP: 6.Next-Gen Inhibitors Shaping Cholangiocarcinoma Treatment Landscape
EP: 7.Key Highlights For Patient Education Surrounding FGFR Inhibitors
EP: 8.Common Adverse Events Associated With FGFRi Therapy
EP: 9.Patient Perspective Regarding FGFRi Adverse Event Profiles
EP: 10.Symptoms Associated With Eye-Related Toxicities Amid FGFRi Therapy
EP: 11.Monitoring and Managing Hyperphosphatemia
EP: 12.Navigating FGFRi Therapy Adverse Effects: Nail Toxicities
EP: 13.FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life
EP: 14.Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma
This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
This is a video synopsis/summary of an OncLive Insights involving Lipika Goyal, MD; Chaundra Bishop; R. Katie Kelley, MD; and Caroline Kuhlman, NP.
FGFR inhibitors such as pemigatinib and futibatinib can cause several adverse effects, including hyperphosphatemia, nail toxicities, stomatitis, and dry mouth. It is critical that patients report all adverse effects fully to their care team for optimal management. Early intervention can often control symptoms without needing treatment discontinuation. Practitioners should set expectations up front for frequent adverse effects such as nail changes, which will happen to virtually all patients to some degree. However, most adverse effects, although bothersome, are not dangerous or severe enough to require hospitalizations. The efficacy of FGFR inhibitors makes it worthwhile to perseverate through short-term quality of life impacts. Proactive strategies for adverse effect prevention and treatment allow most patients to remain on therapy long term. Ultimately, the goal is maximizing time on treatment to achieve prolonged disease control.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
